Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with glioma: a meta-analysis

Table 3 Subgroup analysis of prognostic role of LMR for progression-free survival in patients with glioma

Subgroups	No. of studies	No. of patients	Effects model	HR (95%CI)	p	Heterogeneity
Subgroups	No. of studies	No. of patients	Effects model	HR (95%CI)	p	I² (%)	Ph
Total	3	958	Random	1.20 (0.75–1.91)	0.442	81.7	0.004
Country
China	2	550	Random	1.00 (0.65–1.55)	0.997	78.2	0.032
Others	1	408	-	1.89 (1.14–3.11)	0.013	-	-
Histological type
Glioma	1	318	-	0.81 (0.64–1.03)	0.089	-	-
GBM	2	640	Fixed	1.43 (1.09–1.88)	0.011	40.9	0.194
Treatment
Surgery	1	408	-	1.89 (1.14–3.11)	0.013	-	-
Mixed	2	550	Random	1.00 (0.65–1.55)	0.997	78.2	0.032
Cut-off value
≤ 3.7	2	640	Fixed	1.43 (1.09–1.88)	0.011	40.9	0.194
> 3.7	1	318	-	0.81 (0.64–1.03)	0.089	-	-
Cut-off determination
X-tile	1	408	-	1.89 (1.14–3.11)	0.013	-	-
ROC curve	2	550	Random	1.00 (0.65–1.55)	0.997	78.2	0.032

ISSN: 1741-7015